vs
Side-by-side financial comparison of Dexcom (DXCM) and ResMed (RMD). Click either name above to swap in a different company.
ResMed is the larger business by last-quarter revenue ($1.4B vs $1.3B, roughly 1.1× Dexcom). ResMed runs the higher net margin — 27.6% vs 21.2%, a 6.4% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 11.0%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 7.8%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.
DXCM vs RMD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.4B |
| Net Profit | $267.3M | $392.6M |
| Gross Margin | 62.9% | 61.8% |
| Operating Margin | 25.6% | 34.6% |
| Net Margin | 21.2% | 27.6% |
| Revenue YoY | 21.6% | 11.0% |
| Net Profit YoY | 153.6% | 13.9% |
| EPS (diluted) | $0.67 | $2.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $1.4B | ||
| Q1 26 | $1.3B | $1.4B | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $994.2M | $1.2B |
| Q2 26 | — | $392.6M | ||
| Q1 26 | $267.3M | $398.7M | ||
| Q4 25 | $267.3M | $392.6M | ||
| Q3 25 | $283.8M | $348.5M | ||
| Q2 25 | $179.8M | $379.7M | ||
| Q1 25 | $105.4M | $365.0M | ||
| Q4 24 | $151.7M | $344.6M | ||
| Q3 24 | $134.6M | $311.4M |
| Q2 26 | — | 61.8% | ||
| Q1 26 | 62.9% | 62.2% | ||
| Q4 25 | 62.9% | 61.8% | ||
| Q3 25 | 60.5% | 61.5% | ||
| Q2 25 | 59.5% | 60.8% | ||
| Q1 25 | 56.9% | 59.3% | ||
| Q4 24 | 58.9% | 58.6% | ||
| Q3 24 | 59.7% | 58.6% |
| Q2 26 | — | 34.6% | ||
| Q1 26 | 25.6% | 34.9% | ||
| Q4 25 | 25.6% | 34.6% | ||
| Q3 25 | 20.1% | 33.4% | ||
| Q2 25 | 18.4% | 33.7% | ||
| Q1 25 | 12.9% | 33.0% | ||
| Q4 24 | 17.0% | 32.5% | ||
| Q3 24 | 15.3% | 31.6% |
| Q2 26 | — | 27.6% | ||
| Q1 26 | 21.2% | 27.9% | ||
| Q4 25 | 21.2% | 27.6% | ||
| Q3 25 | 23.5% | 26.1% | ||
| Q2 25 | 15.5% | 28.2% | ||
| Q1 25 | 10.2% | 28.3% | ||
| Q4 24 | 13.6% | 26.9% | ||
| Q3 24 | 13.5% | 25.4% |
| Q2 26 | — | $2.68 | ||
| Q1 26 | $0.67 | $2.74 | ||
| Q4 25 | $0.67 | $2.68 | ||
| Q3 25 | $0.70 | $2.37 | ||
| Q2 25 | $0.45 | $2.58 | ||
| Q1 25 | $0.27 | $2.48 | ||
| Q4 24 | $0.37 | $2.34 | ||
| Q3 24 | $0.34 | $2.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $1.4B |
| Total DebtLower is stronger | — | $663.8M |
| Stockholders' EquityBook value | $2.7B | $6.3B |
| Total Assets | $6.3B | $8.5B |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $1.4B | ||
| Q1 26 | $917.7M | $1.7B | ||
| Q4 25 | $917.7M | $1.4B | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $904.9M | $932.7M | ||
| Q4 24 | $606.1M | $521.9M | ||
| Q3 24 | $621.2M | $426.4M |
| Q2 26 | — | $663.8M | ||
| Q1 26 | — | $664.1M | ||
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M |
| Q2 26 | — | $6.3B | ||
| Q1 26 | $2.7B | $6.5B | ||
| Q4 25 | $2.7B | $6.3B | ||
| Q3 25 | $2.7B | $6.1B | ||
| Q2 25 | $2.6B | $6.0B | ||
| Q1 25 | $2.3B | $5.5B | ||
| Q4 24 | $2.1B | $5.3B | ||
| Q3 24 | $2.0B | $5.2B |
| Q2 26 | — | $8.5B | ||
| Q1 26 | $6.3B | $8.8B | ||
| Q4 25 | $6.3B | $8.5B | ||
| Q3 25 | $7.5B | $8.3B | ||
| Q2 25 | $7.3B | $8.2B | ||
| Q1 25 | $6.8B | $7.6B | ||
| Q4 24 | $6.5B | $7.1B | ||
| Q3 24 | $6.4B | $7.2B |
| Q2 26 | — | 0.11× | ||
| Q1 26 | — | 0.10× | ||
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
